NCT02099071View on ClinicalTrials.gov

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Healthy Subjects
Interventions
DRUG

ACT-389949 1 mg

DRUG

ACT-389949 5 mg

DRUG

ACT-389949 20 mg

DRUG

ACT-389949 50 mg

DRUG

ACT-389949 100 mg

DRUG

ACT-389949 200 mg

DRUG

ACT-389949 500 mg

DRUG

ACT-389949 1000 mg

DRUG

Placebo

Trial Locations (1)

9713 GZ

QPS Netherlands BV, Groningen

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT02099071 - Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949 | Biotech Hunter | Biotech Hunter